ARCT · Arcturus Therapeutics Holdings Inc.

Current Thesis

Arcturus Therapeutics’ regained vaccine rights underpin a revaluation thesis that requires ARCT-810 clinical data and a stated regulatory development path by 2026-09-30. That deadline remains a guidance boundary, not a scheduled announcement: the company’s 2026-08-06 release promised the disclosure during the third quarter. Q2 release

Since the 2026-08-30 assessment, attention has gained dated company events while price momentum has moderated. The adjusted reference close was $14.73 on 2026-09-11, versus $15.19 on 2026-08-28; the 14-day relative strength index (RSI) was 56.3 versus 89.6 on those dates. The inference is that the narrative is maturing — September conference appearances have extended the August rights-return story, but the reference close remains below its August 28 reading. The company’s release archive, checked on 2026-09-13, lists its August 31 conference announcement as the latest release; it does not establish what was discussed in individual webcasts. Release archive

Bullish and bearish views on Arcturus Therapeutics Holdings Inc.

The model's bull view on Arcturus Therapeutics Holdings Inc. (ARCT), in brief: Rights returned with financial relief. The 2026-08-06 settlement disclosure reported global KOSTAIVE and infectious-disease portfolio rights returning alongside $12 million in cash and approximately $16 million in released liabilities and research credits. These are concrete… The bear view: Tolerability needs fuller disclosure. The 2026-08-25 filed symposium poster states that one participant received only four doses because of elevated transaminases, which subsequently resolved without treatment. That observation belongs in the clinical assessment; it does not… Both cases follow in full.

Bull Case

• Rights returned with financial relief. The 2026-08-06 settlement disclosure reported global KOSTAIVE and infectious-disease portfolio rights returning alongside $12 million in cash and approximately $16 million in released liabilities and research credits. These are concrete settlement benefits; future commercialization remains unproven. Q2 release
• Clinical disclosure has a boundary. On 2026-08-06, Arcturus said ARCT-810 Phase 2 enrollment and dosing were complete and guided data and regulatory plans for the third quarter. Completion supports the disclosure timetable, without establishing efficacy. Q2 release
• Analyst attention continued into September. MarketBeat records Roth Capital reiterating its rating with a $41 price target on 2026-09-02. This is Roth’s valuation opinion, not clinical evidence or a dossier price objective. Analyst record

Bear Case

• Tolerability needs fuller disclosure. The 2026-08-25 filed symposium poster states that one participant received only four doses because of elevated transaminases, which subsequently resolved without treatment. That observation belongs in the clinical assessment; it does not establish the frequency of liver-related adverse events in a broader population. Filed poster
• Momentum is weaker than before. The supplied adjusted series records a $14.73 close and RSI of 56.3 on 2026-09-11, below the corresponding $15.19 and 89.6 readings on 2026-08-28. The longer-window advance therefore does not establish renewed near-term acceleration.
• Runway remains management guidance. The 2026-08-06 release reported $191.5 million of cash and equivalents at 2026-06-30 and projected runway through year-end 2028. The same release placed the ARCT-032 Phase 3 decision in the fourth quarter of 2026. Q2 release

Setup & Price Structure

The supplied adjusted series shows a three-month price increase of 111.3% through 2026-09-11, while the $14.73 reference close remained 36.4% below the series’ $23.16 trailing-year high. These describe different windows; neither proves a completed base. Moving-average levels and a volume series are missing, so distance above a rising average and participation breadth cannot be assessed.

The $12 threshold remains the research invalidation published on 2026-08-30. It is not presented as newly verified chart support. A weekly close below $12 ends the price component of the revaluation thesis.

Attention is observable through the company’s September 8, 9 and 10 conference schedule and its upcoming September 15 and 29 appearances, announced on 2026-08-31. That clustering measures corporate exposure, not investor ownership. The available evidence does not establish crowded positioning, insider distribution or issuance into the advance. Conference announcement

Catalyst Calendar (next 30 days)

• 2026-09-29 — ROTH investor meetings. The same August 31 announcement confirms meetings, without promising a public clinical disclosure. Conference announcement
• 2026-09-30 — Guided disclosure boundary. This is quarter-end for the ARCT-810 data and regulatory-plan guidance issued on 2026-08-06, rather than a confirmed event date. Q2 release

Elapsed catalysts

• 2026-09-15 — H.C. Wainwright presentation. The company’s 2026-08-31 announcement schedules the presentation for 11:30 a.m. Eastern. It provides a public communication opportunity; the announcement does not designate it as the clinical readout. Conference announcement (passed 5d ago)

What Would Change Our Mind

Failure to convert the completed ARCT-810 study into disclosed data and a stated regulatory development path by 2026-09-30 breaks the near-term clinical thesis. Independently, a weekly close below $12 invalidates the published price structure. The affirmative case requires the promised disclosure by that boundary, including an identified next regulatory step; conference attendance or an analyst target alone does not satisfy it.

Conviction remains low because the August 6 guidance establishes timing, while the August 25 poster observation leaves tolerability questions for the fuller disclosure. A reliable clinical success probability cannot be inferred from those disclosures alone.

Correlation Notes

This remains a single-company clinical setup. The 2026-08-20 coverage of Moderna and Merck’s messenger RNA vaccine research documents attention to the broader technology, but it supplies no ARCT-810 efficacy evidence. No paired return series is available to quantify ARCT’s correlation with Moderna or biotechnology indices; shared technology does not establish shared price behavior.